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ABSTRACT
The multicenter international Society for Immunotherapy of Cancer (SITC) study of the consensus 
Immunoscore demonstrated the prediction of survival and response to chemotherapy in 763 Stage III 
colon cancer (CC) patients. Similar Immunoscore groups were found in elderly patients, and densities of 
immune cells and intratumoral T-cell repertoire were not decreasing with age in the tumor microenviron-
ment. In two independent cohorts, Immunoscore significantly predicted time to recurrence (TTR), disease- 
free survival (DFS), and overall survival (OS), including within high-risk (T4 or N2) and low-risk (T1-3, N1) 
patients. In stratified Cox multivariable analysis for TTR, DFS, and OS, Immunoscore’s association to 
outcomes was independent of the patient’s age, sidedness, gender, T-stage, N-stage, and microsatellite 
instability status. Furthermore, the relative contribution to the risk test showed that Immunoscore had the 
highest contribution to survival. Importantly Immunoscore predicted the likelihood of response to 
chemotherapy. Only patients with a high-Immunoscore significantly benefited from chemotherapy. The 
prognostic value of Immunoscore was confirmed in two independent phase 3 clinical trials (NCCTG- 
N0147, n = 559; Prodige-IDEA, n = 1062). Moreover, results from IDEA phase 3 randomized trial revealed 
the predictive value of Immunoscore for response to adjuvant FOLFOX chemotherapy duration. The latest 
edition of the WHO Digestive System Tumors classification introduced the immune response as measured 
by Immunoscore as essential and desirable diagnostic criteria for CC, and Immunoscore was introduced 
into the 2020 ESMO Clinical Practice Guidelines for CC to refine the prognosis and adjust chemotherapy 
decision-making process in stages II and III patients. These results highlight the clinical utility of 
Immunoscore.
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Clinical utility of immunoscore in stage III colon 
cancer
A meta-analysis of the literature including more than 200 
published articles for the implication of cytotoxic T-cells and 
T-cell subpopulations with regard to prognosis of cancer 
patients (in 20 different cancer types) revealed that cytotoxic 
CD8 + T-cells were associated with a good prognosis in 97% of 
the studies.1 We previously showed that tumor recurrence and 
overall survival times of patients with colon cancer were mostly 
dependent on the presence of cytotoxic and memory T cells 
within specific regions of primary tumors. We performed 
a clinical study on human colorectal cancer showing that 
cytotoxic and memory T-cells were predicting the clinical out-
come in early Stage (I/II) colorectal cancer patients. We further 
showed that histopathologic-based prognostic factors of color-
ectal cancers are associated with the state of the local immune 
reaction. The assessment of CD8(+) cytotoxic T lymphocytes 
in combined tumor regions provided an indicator of tumor 
recurrence beyond that predicted by AJCC/UICC-TNM 
staging.2–4 The importance of the patient intratumor natural 
adaptive immune reaction for the survival of patients revealed 
that immune parameters are beyond tumor progression and 
invasion (TNM classification). This immune response was 
defined as the “Immunoscore”.1,5–7
The results of an international Immunoscore consortium 
on Stage I/II/III colon cancer patients using the first world-
wide recognized and standardized consensus assay to quan-
tify the preexisting immunity were published. The results 
showed that Immunoscore significantly predicted time to 
recurrence (TTR), disease-free survival (DFS) and overall 
survival (OS). Secondly, Immunoscore predicted high-risk 
and low-risk patients in the restricted population of Stage II 
colon cancer patients. This established the consensus as 
a robust and powerful stratifier to predict the prognosis of 
colon cancer patients.8 Before the inclusion of an immune 
parameter into the TNM-staging system, to move to a TNM- 
Immune (TNM-I) classification, it is important to also 
demonstrate the clinical utility of Immunoscore at each 
stage of the current staging-system. Thus, the clinical utility 
of Immunoscore has been reinforced by the recent publica-
tions demonstrating the prognosis value of Immunoscore in 
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Stage III CC patients, and its predictive value in response to 
chemotherapy.
Recently, the multicenter international Society for 
Immunotherapy of Cancer (SITC) study of the consensus 
Immunoscore demonstrated the prediction of survival and 
response to chemotherapy in Stage III colon cancer.9 This 
international study led by the SITC evaluated the pre-defined 
consensus Immunoscore in 763 patients with AJCC/UICC- 
TNM Stage III CC from 2 cohorts, a first cohort (Canada/ 
USA) and a second cohort (Europe/Asia). The consensus 
Immunoscore was evaluated by quantifying the CD3+ and 
cytotoxic CD8 + T-lymphocyte densities in the tumor and 
invasive-margin by digital-pathology using pre-defined cut- 
points and categories. The lowest risk of recurrence was 
observed in patients with a high-Immunoscore in both cohorts. 
Immunoscore Low, Intermediate and High had recurrence- 
free rates at 3 y of 56.9%, 65.9%, and 76.4%, respectively, with 
a significant hazard-ratio of 0.48 (P= .0003). Significant (all 
P< .001) association with prolonged TTR, OS and DFS were 
found for patients having a High-Immunoscore . 
Immunoscore association to TTR was independent 
(P = .0003) of patient’s gender, T-stage, N-stage, sidedness, 
and microsatellite instability-status, in Cox multivariable ana-
lysis. Significant association of High-Immunoscore with pro-
longed TTR was also found among MSS patients (P = .0003). 
Importantly, Immunoscore had the strongest contribution for 
influencing survival (TTR and OS) as measured with Х2 pro-
portion statistical analysis. Patients with a high-Immunoscore 
responded to chemotherapy and had prolonged survival com-
pared to patients not receiving chemotherapy. In contrast, 
Low-Immunoscore patients did not significantly benefit from 
chemotherapy treatment. Furthermore, the predictive value of 
Figure 1. Clinical utility of the Immunoscore. (a) Immunoscore and intratumoral T-cell repertoire remain stable with age. (b) Relative contribution of each risk parameter 
to survival risk for overall survival in Stage III CC using the x2 proportion test for clinical parameters and Immunoscore. (c) Immunoscore is a powerful prognosis marker 
and a predictive marker of response to chemotherapy for stage III colon cancer patients.
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a high-Immunoscore for response to chemotherapy and pro-
longed survival was found for both low-risk (T1-3, N1) 
(HR = 0.42, P= .001) and high-risk (T4 and/or N2) 
(HR = 0.5, P= .001) patients.
This study demonstrated five key findings.9
First, we showed that densities of immune cells and intra-
tumoral T-cell repertoire are not decreasing with age. 
Furthermore, the same proportion of Immunoscore groups is 
found below 60 y-old and above 85 y-old which is of impor-
tance fundamentally and in considering treatment options.
Second, we demonstrated, in two independent cohorts of 
patients from this international study that Immunoscore sig-
nificantly predicted time to recurrence (TTR), disease-free 
survival (DFS) and overall survival (OS) in Stage III patients.
Third, we showed that Immunoscore predicted outcome 
within the MSS population, and also predicted outcome within 
high-risk (T4 or N2) and low-risk (T1-3, N1) stage III patients.
Fourth, in stratified Cox multivariable analysis for TTR, 
DFS and OS, Immunoscore’s association to outcomes was 
independent of the patient’s age, sidedness, gender, T-stage, 
N-stage, and microsatellite instability (MSI) status. 
Furthermore, the relative contribution to the risk test showed 
that Immunoscore had the highest contribution to survival in 
comparison to all other clinical parameters.
Fifth, importantly Immunoscore predicted the likelihood of 
response to chemotherapy. Indeed, patients who did not 
receive chemotherapy had similar outcomes as those who 
received chemotherapy, if they had a low-Immunoscore, and 
did not significantly benefit from chemotherapy. In contrast, 
patients with an Intermediate/high-Immunoscore significantly 
benefited from chemotherapy.
This illustrates the fact that the benefit of chemotherapy 
may be dependent upon a proper preexisting immunity 
(Figure 1).
Validation in two randomized phase 3 trials
The results of Immunoscore in Stage III CC patients were 
confirmed in two independent randomized phase 3 clinical 
trials. The Immunoscore-N0147 study was conducted in colla-
boration with clinicians and researchers from the Mayo 
Clinic.10 The study included 559 patient samples from the 
FOLFOX arm of the NCCTG-N0147 trial and used the pre- 
defined consensus Immunoscore. Immunoscore predicted 
relapse and death in stage III CC patients treated with 
a standard adjuvant treatment combining fluoropyrimidine 
and oxaliplatin in the N0147 trial.10 Another randomized 
phase 3 clinical trial (IDEA) in 1062 Stage III CC patients 
tested the consensus Immunoscore.11 The two studies were 
performed, using the pre-defined consensus Immunoscore, 
had similar significant results regarding the prognostic value 
of Immunoscore.
The randomized phase 3 clinical trial IDEA aimed to 
evaluate the non-inferiority of 3 months of chemotherapy 
(FOLFOX or CAPOX) compared to 6 months. The primary 
objective of this trial (IDEA) was not met, and it could not 
be concluded that this non-inferiority was achieved. 
However, the IDEA study showed that 3 months adjuvant 
treatment was associated with a significantly lower 
incidence and severity of adverse events compared to 
6 months. Even if the primary objective of this trial was 
not met, secondary subgroup analyses were carried out and 
showed that CAPOX met the criteria for non-inferiority, 
but not those for FOLFOX. Differences in DFS depending 
on treatment-duration were modest. Based on these data it 
was proposed to treat low-risk patients (T1-3N1) with 
3 months of chemotherapy. However, this study highlighted 
the need for additional biomarkers to predict the efficacy of 
adjuvant chemotherapy in CC patients.
Not only the phase 3 trial IDEA confirmed the prognostic 
value of Immunoscore but it also confirmed its predictive value 
in response to chemotherapy.11 High-Immunoscore patients 
significantly benefited from 6-month treatment compared to 
3month treatment. Conversely, in patients with Low- 
Immunoscore, no significant benefit of 6-month FOLFOX 
was observed compared to 3-month treatment. These results 
were also observed independently of the clinical stage. Both 
high-risk (T4 and/or N2) and low-risk (T1-3, N1) patients sig-
nificantly benefited from 6-month FOLFOX when they had 
a High-Immunoscore, but not when they had a Low- 
Immunoscore. This validated and further demonstrated the 
predictive value of Immunoscore in response to chemotherapy. 
Importantly, clinically low-risk patients (T1-3, N1) with High- 
Immunoscore had 91.4% DFS at 3-y when treated with the 
6-month FOLFOX, but only 80.8% with the 3-month treatment 
regimen. Thus, even low-risk (T1-3, N1) patients with a High- 
Immunoscore could effectively benefit from 6 months of 
FOLFOX, thereby changing clinical practice. Unfortunately, 
patients with Low-Immunoscore (44.6% of Stage III) not only 
had an increased risk of recurrence but also a lack of benefit 
from longer duration of chemotherapy treatment. Given the 
poor outcome in these patients, new therapeutic strategies and 
clinical trials should be initiated in this population. FOLFOX 
chemotherapy contains 5-fluorouracil and Oxaliplatin. These 
components may have a dual impact on the immune system. 
On one hand, 5-fluorouracil may partially deplete or transi-
ently inactivate inhibitory immune cells, and on the other hand 
oxaliplatin may increase cytotoxic T-cell infiltration and 
induce immunogenic cell death (ICD).12–14 It could be 
hypothesized that ICD-driven immunity is inefficient in 
tumors with a weak preexisting immunity such as Low- 
Immunoscore patients. Thus, it will be important to identify 
Immunoscore-Low patients to test combination immu-
notherapies that can prime and expand anti-cancer immunity 
in this population, in order to prolong their survival.
Conclusions
These results highlight the prognostic value of Immunoscore 
regardless of the patient’s age. It further strengthens the Level 
of Evidence and clinical utility of Immunoscore in stage III CC 
patients. The Immunoscore assay has been developed as an 
in vitro diagnostic test (CE-IVD) and is available in FDA CLIA- 
certified laboratories for routine use. Importantly, in the latest 
(5th) edition of the WHO Digestive System Tumors classifica-
tion, was introduced “the immune response as essential and 
desirable diagnostic criteria for colorectal cancer,” and citing the 
consensus Immunoscore as best clinical evidence in colon 
ONCOIMMUNOLOGY 3
cancer. Furthermore, Immunoscore was introduced into the 
2020 ESMO Clinical Practice Guidelines for colon cancer to 
refine the prognosis and thus adjust the chemotherapy decision- 
making process in stage II and even in low-risk stage III patients. 
The results of Immunoscore in the multicenter international 
SITC study and the recent inclusions into WHO and ESMO 
guidelines argue for the benefit of implementing the 
Immunoscore in clinical practice and for its introduction in 
a new TNM-Immune (TNMI) classification system.
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